Immune checkpoint inhibitors (ICIs) are highly effective as they target inhibitory co-stimulatory molecules such as PD-1 and CTLA-4 on CAR-T lymphocyte surfaces, improve tumor control, and maintain T cell persistence (Sharma and Allison, 2015). Here, PDCD1 is linked to neoplasm.